HC Wainwright restated their buy rating on shares of XOMA (NASDAQ:XOMA – Free Report) in a research report report published on Friday morning, Benzinga reports. HC Wainwright currently has a $117.00 price objective on the biotechnology company’s stock.
Separately, StockNews.com raised shares of XOMA from a sell rating to a hold rating in a research report on Wednesday, August 14th.
Get Our Latest Research Report on XOMA
XOMA Price Performance
XOMA (NASDAQ:XOMA – Get Free Report) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $11.09 million for the quarter, compared to analysts’ expectations of $8.37 million. XOMA had a negative return on equity of 24.50% and a negative net margin of 128.59%. As a group, research analysts predict that XOMA will post -1.42 EPS for the current year.
Institutional Investors Weigh In On XOMA
A number of large investors have recently modified their holdings of XOMA. Bank of New York Mellon Corp grew its holdings in XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Rhumbline Advisers lifted its holdings in XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after buying an additional 1,334 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in XOMA in the 1st quarter valued at about $212,000. Finally, BNP Paribas Financial Markets grew its stake in shares of XOMA by 55.6% during the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,266 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.
About XOMA
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Read More
- Five stocks we like better than XOMA
- 5 discounted opportunities for dividend growth investors
- The Average 401k Balance by Age Explained
- Dividend Capture Strategy: What You Need to Know
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Top Stocks Investing in 5G Technology
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.